Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.

Menno TammingaSanne de WitT Jeroen N HiltermannWim TimensEd SchuuringLeon W M M TerstappenHarry J M Groen

Published in: Journal for immunotherapy of cancer (2019)

CTC occur in one third of advanced NSCLC patients and their presence is a predictive factor for a worse durable response rate to checkpoint inhibitors. tdEV are associated with shorter survival but not with response.

Keyphrases

advanced non small cell lung cancer
circulating tumor cells
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
dna damage
small cell lung cancer
prognostic factors
peritoneal dialysis
cell cycle
epidermal growth factor receptor
circulating tumor